|
|
 |
BioVaria Roundtable: What does it Take to Put Ideas into Practice?
In April this year, Removab, an anti-cancer antibody originating from the Helmholtz Zentrum München, obtained EU approval. Together with Ixempra and Gardasil it is the third anti-cancer drug discovered by Helmholtz scientists that is now available to patients. It is the first, however, that has been brought to market by a spin-out in collaboration with an industry partner. These successes clearly demonstrate what publicly-funded research has to offer. The crucial question is: What does it take to exploit this potential? more
What Removab Approval Means to Ascenion and its Partners
When Ascenion was formed in 2001, we set out with the goal of reaching break-even in about 7 years. For some of our partner institutions, we attained this years ago:more
Inventor ProfileWolfgang Meyerhof: Bitter insights from taste research
Wolfgang Meyerhof, one of the most prominent taste researchers worldwide, started his academic career in the field of developmental biology, looking into the embryonic development of amphibians. What made him move to taste research in the 1990s was not his passion for food, but rather the chance to explore new ground.more
Ascenion's Results
In 2008, Ascenion supported 73 patent applications, mediated 71 agreements with industry and closed 4 spin-off deals.more
Life-Science Foundation: Non-scientific Services for Scientists
Be honest - do you know, how Ascenion's parent holding, the Life-Science Foundation for the Promotion of Science and Research, is doing? Or what its purpose exactly is? We spoke to Wilhelm Wolf, Director of the Life Science Foundation about the foundation's development and goals.more
Spinning InnovationKinaris Biomedicals - Targeting motor protein triggered cell motility
Myosins are prominent motor proteins found in virtually all eukaryotic cells that drive a broad range of movements such as cell motility, muscular contraction, cytokinesis, membrane trafficking and signal transduction. Some myosins are also involved in the development of diseases more MBiotec - Discovered by chance, developed over decades: New anti-cancer compound
Back in the 1980s, Prof. Peter Mühlradt and his team observed a puzzling effect that a cell culture supernatant had on certain immune cells from the thymus gland. Initially, they assumed that they had discovered novel cytokines, as was the primary intention of their work.more
Turning Science into Business OpportunitiesVPM: Moving vaccines from the bench to the bedside
In December 2008, Ascenion acquired equity in Vakzine Projekt Management GmbH (VPM), a company which was set up in 2002 as a public-private partnership by the Helmholtz Centre for Infection Research (HZI) and the German Federal Ministry of Education and Research (BMBF). more
Fostering NetworksWorkshops "Translational Medicine"
In collaboration with three institutes of the Leibniz Association (BNI, HPI, FZB), Ascenion has planned a series of educational workshops to help scientists integrate "translational thinking" into their work. more 3rd Biotech Networkshop: Learn from seasoned managers
Sixty-two participants joined this year's Biotech Networkshop, held on 4th-6th of March at the Evangelische Akademie Tutzing. About half were biotech entrepreneurs; the other half were experts in financing, business development, legal or communication and CEOs of Germany's most established biotech companies..more
|
Meet us at the forthcoming events: STS Forum, October 4-6, 2009, Kyoto, Japan
News in Brief:
Contact us: Munich: |
